Clinical trials · Raleigh–Durham, NC
Cancer clinical trials in Raleigh–Durham
We’re tracking 430 recruiting cancer studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT06497569Recruiting
Support program for people with gastroesophageal cancer
This study offers remote nutrition guidance and support for people with gastroesophageal cancer who are starting chemotherapy or radiation. The goal is to help you stay strong and manage side effects during treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT07084168Recruiting
Video tool to help with genetic testing for ovarian or endometrial cancer
This study tests a multimedia tool designed to help people with ovarian or endometrial cancer understand and decide about genetic testing. The tool may make it easier to learn about genetic testing options and make informed choices.
Chapel Hill, North CarolinaAges 18 years+ - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
Chapel Hill, North CarolinaAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Chapel Hill, North CarolinaAges 18–79 - NCT06560021Enrolling by invitation
Random biopsies in inflammatory bowel disease surveillance
This trial looks at whether taking random biopsies during a routine colonoscopy is helpful for people with inflammatory bowel disease (IBD) who are at risk for colon cancer. It aims to understand if random biopsies can detect early signs of cancer or pre-cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06252545Recruiting
Improving clinical trial engagement for pancreatic cancer with an app
This study is about improving how Black individuals with pancreatic cancer connect with clinical trials, using a smartphone app. You would participate in a 1-hour interview to share your experiences.
Chapel Hill, North CarolinaAges 18 years+ - NCT06096038RecruitingPhase 1
CAR-T cell therapy for head and neck cancer
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Chapel Hill, North CarolinaAges 18 years+ - NCT06902376RecruitingPhase 1
XL092 and cemiplimab for advanced thyroid cancer without BRAF mutation
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Chapel Hill, North CarolinaAges 18 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Chapel Hill, North CarolinaAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
Chapel Hill, North CarolinaAges 18 years+ - NCT05440929Recruiting
Testing a breast-cancer prognostic tool with U.S. clinicians
This study checks how acceptable, appropriate, and easy to use a metastatic breast-cancer “prognostic calculator” is for clinicians. It may help clinicians use the tool in real practice to support care decisions for people with metastatic breast cancer.
Chapel Hill, North CarolinaAges Any age - NCT06697600Recruiting
Supporting decisions for older adults with AML and their caregivers
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
Chapel Hill, North CarolinaAges 60 years+ - NCT05557877RecruitingPhase 2
Low-dose aspirin to prevent postpartum breast cancer
This study tests whether taking a low dose of aspirin after childbirth can lower the chance of developing breast cancer later. You may be asked to provide blood, urine, and breast tissue samples so researchers can look for changes that could explain why aspirin may help.
Chapel Hill, North CarolinaAges 18–45 - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Chapel Hill, North CarolinaAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
Chapel Hill, North CarolinaAges 18 years+ - NCT06674889Recruiting
Cancer rehabilitation study for daily activities and mobility
This study looks at how cancer rehabilitation services can help patients who have trouble with daily activities, feel unsteady, or want to exercise more. It aims to improve your function and quality of life during cancer care.
Chapel Hill, North CarolinaAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Chapel Hill, North CarolinaAges 18 years+ - NCT06158139RecruitingPhase 1
Testing modified immune cells for pancreatic cancer
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06687603Recruiting
Detecting Barrett's esophagus in people without heartburn
This study aims to screen for Barrett's esophagus in people who are getting a routine colonoscopy but do not have chronic heartburn. It uses a simple, non-invasive cell collection device (EsoCheck) to see if you might have Barrett's esophagus, which can increase the risk of esophageal cancer.
Chapel Hill, North CarolinaAges 50 years+ - NCT07630168RecruitingPhase 2
Does infusion timing affect treatment response in solid tumors?
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
Chapel Hill, North CarolinaAges 18 years+ - NCT05874921Recruiting
Registry for adults with UTUC treated with Jelmyto
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new Cancer trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting cancer studies listed above.
- UNC Lineberger Comprehensive Cancer Center · 5 studies
- University of North Carolina · 5 studies
- University of North Carolina at Chapel Hill · 5 studies
- Avenzo Therapeutics Recruiting Site
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
- The N.C. Cancer Hospital
- The University of North Carolina Chapel Hill
- UNC Hospitals
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in North Carolina.
Common questions
- Are there cancer clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 430 recruiting cancer studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.